Suppr超能文献

对急性心肌梗死患者在给予链激酶或阿尼普酶后长达30个月的链激酶抗性滴度进行监测,以及进行相关研究以测定特异性抗链激酶IgG。

Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG.

作者信息

Fears R, Ferres H, Glasgow E, Standring R, Hogg K J, Gemmill J D, Burns J M, Rae A P, Dunn F G, Hillis W S

机构信息

SmithKline Beecham Pharmaceuticals, Great Burgh, Epsom, Surrey.

出版信息

Br Heart J. 1992 Aug;68(2):167-70. doi: 10.1136/hrt.68.8.167.

Abstract

OBJECTIVE

To examine the induction of antistreptokinase antibodies after giving streptokinase or anistreplase to patients with acute myocardial infarction.

DESIGN

Patients were randomly allocated to receive either 1.5 x 10(6) IU, streptokinase or 30U anistreplase in a double blind study. Blood samples were collected immediately before treatment and subsequently at intervals up to 30 months; plasma samples were assayed for streptokinase resistance titre (functional assay) and streptokinase binding by IgG (microradioimmunoassay).

SETTING

Cardiology department in a general hospital.

PATIENTS

128 consecutive eligible patients. Samples were collected for up to one year according to a prospective design: a subsection of 47 patients was selected for intensive study over the first 14 days. After one year, all available patients (67) were sampled on one further occasion.

RESULTS

Antibody responses to streptokinase and anistreplase were similar. Streptokinase resistance titres exceeded pretreatment concentrations five days after dosing, and values peaked at 14 days. By 12 months after dosing, 92% of resistance titres (n = 84) had returned to within the pretreatment range. Antistreptokinase IgG concentrations also exceeded baseline concentrations within five days and peaked at 14 days. Half of the individual values had returned to within the pretreatment range by 12 months (n = 84) and 89% by 30 months (n = 18).

CONCLUSION

Although we cannot be sure of the clinical significance, because of the increased likelihood of resistance due to antistreptokinase antibody, streptokinase and anistreplase may not be effective if administered more than five days after an earlier dose of streptokinase or anistreplase, particularly between five days and 12 months, and increased antistreptokinase antibody may increase the risk of allergic-type reactions.

摘要

目的

研究急性心肌梗死患者接受链激酶或茴香酰化纤溶酶原链激酶激活剂治疗后抗链激酶抗体的诱导情况。

设计

在一项双盲研究中,患者被随机分配接受1.5×10⁶IU链激酶或30U茴香酰化纤溶酶原链激酶激活剂治疗。在治疗前即刻及随后长达30个月的时间间隔内采集血样;检测血浆样本中的链激酶抵抗滴度(功能测定)以及IgG对链激酶的结合情况(微量放射免疫测定)。

地点

一家综合医院的心脏病科。

患者

128例连续符合条件的患者。根据前瞻性设计,样本采集长达一年:选取47例患者的一个亚组在最初14天进行深入研究。一年后,对所有可获得的患者(67例)再进行一次采样。

结果

对链激酶和茴香酰化纤溶酶原链激酶激活剂的抗体反应相似。给药后5天,链激酶抵抗滴度超过治疗前浓度,14天时达到峰值。给药后12个月,92%的抵抗滴度(n = 84)恢复到治疗前范围以内。抗链激酶IgG浓度在5天内也超过基线浓度,14天时达到峰值。到12个月时,一半的个体值(n = 84)恢复到治疗前范围以内,到30个月时89%(n = 18)恢复到该范围以内。

结论

尽管由于抗链激酶抗体导致抵抗增加,我们无法确定其临床意义,但如果在较早剂量的链激酶或茴香酰化纤溶酶原链激酶激活剂给药后超过5天给药,尤其是在5天至12个月之间,链激酶和茴香酰化纤溶酶原链激酶激活剂可能无效,并且抗链激酶抗体增加可能会增加过敏样反应的风险。

相似文献

引用本文的文献

1
Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims.青少年自杀者前额皮质中的促炎细胞因子。
J Psychiatr Res. 2012 Jan;46(1):57-63. doi: 10.1016/j.jpsychires.2011.08.006. Epub 2011 Sep 8.
4
BTS guidelines for the management of pleural infection.英国胸科学会胸膜感染管理指南。
Thorax. 2003 May;58 Suppl 2(Suppl 2):ii18-28. doi: 10.1136/thorax.58.suppl_2.ii18.
8
Are streptokinase antibodies clinically important?链激酶抗体在临床上重要吗?
Br Heart J. 1993 Aug;70(2):101-2. doi: 10.1136/hrt.70.2.101.
10
How safe is the readministration of streptokinase?
Drug Saf. 1995 Aug;13(2):76-80. doi: 10.2165/00002018-199513020-00002.

本文引用的文献

8
Antistreptokinase titres after intravenous streptokinase.
Lancet. 1990 Jan 27;335(8683):184-5. doi: 10.1016/0140-6736(90)90276-b.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验